oral glp-1 medication A Pill to Fight Obesity Is on the Verge of Approval Oral Semaglutide for Weight Loss
Description
It can range from mild to disabling and may or may not be neurodegenerative
In a 48-week clinical trial, higher doses consistently led to greater average weight loss: Weight loss by dose (48-week clinical trial) In this trial, at the highest dose (12 mg), people lost an average 24% of their starting weight on average
The Kamel-Abusalha cohort showed a reduced Parkinsonism hazard (HR 0.26), but with low event counts and a wide confidence interval
Alatassi sees her patients once a month when they start on these drugs and then once every three months
